Gilead Sciences Inc

Investors shift on Gilead Sciences: margin erosion, regulatory heads‑wind and ESG risk explain the net outflow, while new drugs and digital health offer hidden upside.

Institutional buying and analyst upgrades highlight Gilead Sciences as a defensive, high‑margin biopharma with a robust oncology pipeline, but patent expirations and regulatory risks remain key considerations.

Gilead’s Trodelvy + Keytruda combo shows a 32% OS boost for metastatic triple‑negative breast cancer, but with higher toxicity—what it means for investors, regulators, and payers.

Gilead Sciences’ future hinges on its HIV prevention shot, new Walgreens partnership, and oncology pipeline, amid divergent analyst outlooks and rising valuation concerns.

Gilead Sciences sees mixed analyst views as Yeztugo, the monthly HIV‑prevention injection, gains FDA approval and CVS Health coverage, boosting sales potential while highlighting valuation uncertainties.

Gilead Sciences’ latest stock gain, new HIV injection approval and legal‑leadership shift boost investor confidence while highlighting its growing pipeline and strategic focus on antiviral therapies.

Explore how Gilead’s Kite sub‑unit’s new bispecific CAR‑T candidates and Yescarta data could reshape oncology reimbursement, margins and investor outlook.

Gilead’s Kite reports breakthrough CAR‑T data for relapsed/refractory large B‑cell lymphoma: Yescarta shows 70 % CR in transplant‑ineligible patients, while dual‑targeting KITE‑753/363 and Arcellx’s iMMagine‑1 deliver 83–78 % ORR and durable remissi…

Gilead’s launch of lenacapavir in sub‑Saharan Africa signals a major HIV prevention breakthrough and a strong investment play as options surge and market access expands.

Gilead’s ARTISTRY‑1 Phase 3 trial shows single‑tablet bictegravir/lenacapavir matches multi‑tablet regimens for virologic suppression, with similar safety and lower pill burden, boosting adherence and cost savings for HIV patients.